GlobeNewswire by notified

Managers’ transactions

Share

December 9, 2023

Announcement no. 21

Managers’ transactions

COPENHAGEN, DENMARK and BOSTON, MA, December 9, 2023, (GLOBE NEWSWIRE) – BioPorto A/S (BioPorto or the Company) (CPH:BIOPOR), has received notice pursuant to article 19 of Regulation (EU) no. 596/2014 of the below transaction related to shares in BioPorto made by persons discharging managerial responsibilities in BioPorto and/or persons closely related with them. 

1. Details of the person discharging managerial responsibilities/person closely associated
a) Name Singer Asefzadeh Family Holding Trust
2. Reason for the notification
a) Position/status Closely associated person to Michael S. Singer, member of the Board of Directors of BioPorto A/S
b) Initial notification/amendment Initial notification
3. Details of the issuer
a) Name BioPorto A/S
b) LEI 5299004SWFL5JAN4W830
4. Details of the transaction(s)
a) Description of the financial instrument type of instrument and Identification code Shares, ISIN code DK0011048619
b) Nature of the transaction Sales of shares
c) Price(s) and volume(s) Price: DKK 3.2011 per share, Volume: 246,224
d) Aggregated information
- Aggregated volume
- Aggregated price
N/A
e) Date of the transaction 8 December 2023, 11:31 a.m. UTC (12:31 p.m. CEST)
f) Place of the transaction Nasdaq Copenhagen A/S, XCSE

For inquiries, please contact

EU Investor Relations
HC Andersen Capital
P: +45 4529 0000
E: investor@bioporto.com

US Investor Relations
Ashley R. Robinson, LifeSci Advisors
P: +1 617 430 7577
E: arr@lifesciadvisors.com

About Acute Kidney Injury

Acute kidney injury is a sudden episode of kidney failure or kidney damage that happens within a few hours or a few days. AKI causes a build-up of waste products in blood and makes it difficult for kidneys to maintain the proper balance of bodily fluids. AKI can also affect other organs such as the brain, heart, and lungs and is common in patients who are in hospital intensive care units. For more information about AKI please visit: https://bioporto.com/aki/

About BioPorto

BioPorto is an in vitro diagnostics company focused on saving lives and improving the quality of life with actionable biomarkers – tools designed to help clinicians make changes in patient management. The Company uses its expertise in antibodies and assay development, as well as its platform for assay development, to create a pipeline of novel and compelling products that focus on conditions where there is significant unmet medical need, and where the Company’s tests can help improve clinical and economic outcomes for patients, providers, and the healthcare ecosystem.

The Company’s flagship products are based on the NGAL biomarker and designed to aid in the risk assessment and diagnosis of Acute Kidney Injury, a common clinical syndrome that can have severe consequences, including significant morbidity and mortality, if not identified and treated early. With the aid of NGAL levels, physicians can identify patients potentially at risk of AKI more rapidly than is possible with current standard of care measurements, enabling earlier intervention and more tailored patient management strategies. The Company markets NGAL tests under applicable registrations including CE mark in several countries worldwide.

BioPorto has facilities in Copenhagen, Denmark and Boston, MA, USA. The shares of BioPorto A/S are listed on the Nasdaq Copenhagen stock exchange. For more information visit www.bioporto.com.

Attachment

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Ekstraordinære indfrielser (CK93) - Nykredit Realkredit A/S26.2.2024 11:22:00 CET | pressemeddelelse

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Nykredit Realkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 23. Februar 2024 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Nykredit Realkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Nykredit Realkredit A_S - 26-02-2024XMLeordindf

Prepayments (CK93) - Nykredit Realkredit A/S26.2.2024 11:22:00 CET | Press release

To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Nykredit Realkredit A/S hereby publishes prepayment data (CK93) as at 23 February 2024 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Nykredit Realkredit A/S Attachments Prepayments - Nykredit Realkredit A_S - 26-02-2024XMLeordindf

Ekstraordinære indfrielser (CK93) - Totalkredit A/S26.2.2024 11:22:00 CET | pressemeddelelse

Til Nasdaq Copenhagen Ekstraordinære indfrielser (CK93) I medfør af kapitalmarkedsloven § 24 offentliggør Totalkredit A/S hermed oplysninger om ekstraordinære indfrielser (CK93) pr. den 23. februar 2024 i vedhæftede fil. Oplysningerne vil endvidere på sædvanlig måde blive formidlet via Nasdaq Copenhagen. Oplysningerne findes også i excel-format i Nykredits obligationsdatabase på https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For yderligere informationer om dataformat og -indhold henvises til Nasdaqs hjemmeside. Spørgsmål kan rettes til head of investor relations Morten Bækmand Nielsen på tlf. 44 55 15 21. Med venlig hilsen Totalkredit A/S Vedhæftede filer Ekstraordinære indfrielser - Totalkredit A_S-26-02-2024XML_eordindftk

Prepayments (CK93) - Totalkredit A/S26.2.2024 11:22:00 CET | Press release

To the Nasdaq Copenhagen Prepayments (CK93) Pursuant to s 24 of the Danish Capital Markets Act, Totalkredit A/S hereby publishes prepayment data (CK93) as at 23 February 2024 in the attached file. Furthermore, the data will be distributed in the usual way through Nasdaq Copenhagen. Data on Nykredit and Totalkredit bonds is also available by ISIN code in Excel format on https://www.nykredit.com/en-gb/investor-relations/financial-reporting/prepayments/. For further information about data format and contents, please refer to the Nasdaq website. Questions may be addressed to Morten Bækmand Nielsen, Head of Investor Relations, tel +45 44 55 15 21. Yours sincerely Totalkredit A/S Attachments Prepayments - Totalkredit A_S-26-02-2024XML_eordindftk

Transactions in connection with share buy-back program26.2.2024 11:21:11 CET | Press release

Company Announcement COPENHAGEN, Denmark; February 26, 2024 – Genmab A/S (Nasdaq: GMAB). On February 14, 2024, Genmab announced the initiation of a share buy-back program to honor our commitments under our Restricted Stock Units program. The share buy-back program is expected to be completed no later than March 15, 2024, and comprises up to 190,000 shares. The following transactions were executed under the program from February 19 to February 23, 2024: No. of sharesAverage price (DKK)Total value (DKK)Accumulated through last announcement23,00046,481,960February 19, 20248,0002,027.4116,219,280 February 20, 202415,0001,995.4729,932,050 February 21, 202416,0001,977.5631,640,960February 22, 202412,0002,003.1424,037,680February 23, 202410,0002,003.2820,032,800Total61,000121,862,770Accumulated under the program84,000168,344,730 Details of each transaction are included as an appendix to this announcement. Following these transactions, Genmab holds 819,891 shares as treasury shares, correspond

HiddenA line styled icon from Orion Icon Library.Eye